Targeting BET Bromodomains for Cancer Treatment

References

• Roy DM , WalshLA , ChanTA . Driver mutations of cancer epigenomes . Protein Cell5 ( 4 ), 265 – 296 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Loven J , HokeHA , LinCYet al. Selective inhibition of tumor oncogenes by disruption of super-enhancers . Cell153 ( 2 ), 320 – 334 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Kurdistani SK . Chromatin: a capacitor of acetate for integrated regulation of gene expression and cell physiology . Curr. Opin. Genet. Dev.26C , 53 – 58 ( 2014 ).
   Google Scholar
• Marmorstein R , ZhouMM . Writers and readers of histone acetylation: structure, mechanism, and inhibition . Cold Spring Harb. Perspect. Biol.6 ( 7 ), a018762 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Slingerland M , GuchelaarHJ , GelderblomH . Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors . Anticancer Drugs25 ( 2 ), 140 – 149 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• West AC , SmythMJ , JohnstoneRW . The anticancer effects of HDAC inhibitors require the immune system . Oncoimmunology3 ( 1 ), e27414 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Gallenkamp D , GelatoKA , HaendlerB , WeinmannH . Bromodomains and their pharmacological inhibitors . ChemMedChem9 , 438 – 464 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Filippakopoulos P , KnappS . Targeting bromodomains: epigenetic readers of lysine acetylation . Nat. Rev. Drug Discov.13 ( 5 ), 337 – 356 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Shi J , VakocCR . The mechanisms behind the therapeutic activity of BET bromodomain inhibition . Mol. Cell54 ( 5 ), 728 – 736 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Filippakopoulos P , QiJ , PicaudSet al. Selective inhibition of BET bromodomains . Nature468 ( 7327 ), 1067 – 1073 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Nicodeme E , JeffreyKL , SchaeferUet al. Suppression of inflammation by a synthetic histone mimic . Nature468 ( 7327 ), 1119 – 1123 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Anders L , GuentherMG , QiJet al. Genome-wide localization of small molecules . Nat. Biotechnol.32 ( 1 ), 92 – 96 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Houzelstein D , BullockSL , LynchDE , GrigorievaEF , WilsonVA , BeddingtonRS . Growth and early postimplantation defects in mice deficient for the bromodomain-containing protein Brd4 . Mol. Cell. Biol.22 ( 11 ), 3794 – 3802 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Lamonica JM , DengW , KadaukeSet al. Bromodomain protein Brd3 associates with acetylated GATA1 to promote its chromatin occupancy at erythroid target genes . Proc. Natl Acad. Sci. USA108 ( 22 ), E159 – E168 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Wang F , DeeneyJT , DenisGV . Brd2 gene disruption causes “metabolically healthy” obesity: epigenetic and chromatin-based mechanisms that uncouple obesity from type 2 diabetes . Vitam. Horm.91 , 49 – 75 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Berkovits BD , WolgemuthDJ . The role of the double bromodomain-containing BET genes during mammalian spermatogenesis . Curr. Top. Dev. Biol.102 , 293 – 326 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Baud MG , Lin-ShiaoE , CardoteTet al. Chemical biology. A bump-and-hole approach to engineer controlled selectivity of BET bromodomain chemical probes . Science346 ( 6209 ), 638 – 641 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Vollmuth F , BlankenfeldtW , GeyerM . Structures of the dual bromodomains of the P-TEFb-activating protein Brd4 at atomic resolution . J. Biol. Chem.284 ( 52 ), 36547 – 36556 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Filippakopoulos P , PicaudS , MangosMet al. Histone recognition and large-scale structural analysis of the human bromodomain family . Cell149 ( 1 ), 214 – 231 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Jung M , PhilpottM , MullerSet al. Affinity Map of BRD4 Interactions with the histone H4 tail and the small molecule inhibitor JQ1 . J. Biol. Chem.289 ( 13 ), 9304 – 9319 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Zhang W , PrakashC , SumCet al. Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells . J. Biol. Chem.287 ( 51 ), 43137 – 43155 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Nishiyama A , DeyA , MiyazakiJ , OzatoK . Brd4 is required for recovery from antimicrotubule drug-induced mitotic arrest: preservation of acetylated chromatin . Mol. Biol. Cell17 ( 2 ), 814 – 823 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Chen R , YikJH , LewQJ , ChaoSH . Brd4 and HEXIM1: multiple roles in P-TEFb regulation and cancer . Biomed. Res. Int.2014 , 232870 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Itzen F , GreifenbergAK , BoskenCA , GeyerM . Brd4 activates P-TEFb for RNA polymerase II CTD phosphorylation . Nucleic Acids Res.42 ( 12 ), 7577 – 7590 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Bisgrove DA , MahmoudiT , HenkleinP , VerdinE . Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription . Proc. Natl Acad. Sci. USA104 ( 34 ), 13690 – 13695 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Schroder S , ChoS , ZengLet al. Two-pronged binding with bromodomain-containing protein 4 liberates positive transcription elongation factor b from inactive ribonucleoprotein complexes . J. Biol. Chem.287 ( 2 ), 1090 – 1099 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Liu W , MaQ , WongKet al. Brd4 and JMJD6-associated anti-pause enhancers in regulation of transcriptional pause release . Cell155 ( 7 ), 1581 – 1595 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Devaiah BN , SingerDS . Two faces of brd4: mitotic bookmark and transcriptional lynchpin . Transcription4 ( 1 ), 13 – 17 ( 2013 ).
   PubMedGoogle Scholar
• Zou Z , HuangB , WuXet al. Brd4 maintains constitutively active NF-kappaB in cancer cells by binding to acetylated RelA . Oncogene33 ( 18 ), 2395 – 2404 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Asangani IA , DommetiVL , WangXet al. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer . Nature510 ( 7504 ), 278 – 282 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Feng Q , ZhangZ , SheaMJet al. An epigenomic approach to therapy for tamoxifen-resistant breast cancer . Cell Res.24 ( 7 ), 809 – 819 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Nagarajan S , HossanT , AlawiMet al. Bromodomain protein BRD4 Is required for estrogen receptor-dependent enhancer activation and gene transcription . Cell Rep.8 ( 2 ), 460 – 469 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Shi J , WangY , ZengLet al. Disrupting the interaction of BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like breast cancer . Cancer Cell25 ( 2 ), 210 – 225 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Wu SY , LeeAY , LaiHT , ZhangH , ChiangCM . Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting . Mol. Cell49 ( 5 ), 843 – 857 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Ray S , ZhaoY , JamaluddinM , EdehCB , LeeC , BrasierAR . Inducible STAT3 NH2 terminal mono-ubiquitination promotes BRD4 complex formation to regulate apoptosis . Cell Signal.26 ( 7 ), 1445 – 1455 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Gamsjaeger R , WebbSR , LamonicaJM , BillinA , BlobelGA , MackayJP . Structural basis and specificity of acetylated transcription factor GATA1 recognition by BET family bromodomain protein Brd3 . Mol. Cell. Biol.31 ( 13 ), 2632 – 2640 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Rahman S , SowaME , OttingerMet al. The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins, including NSD3 . Mol. Cell. Biol.31 ( 13 ), 2641 – 2652 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Bonora G , PlathK , DenholtzM . A mechanistic link between gene regulation and genome architecture in mammalian development . Curr. Opin. Genet. Dev.27C , 92 – 101 ( 2014 ).
   Google Scholar
• Hu X , LuX , LiuRet al. Histone crosstalk connects protein phosphatase 1alpha (PP1alpha) and histone deacetylase (HDAC) pathways to regulate the functional transition of bromodomain-containing 4 (Brd4) for inducible gene expression . J. Biol. Chem.289 ( 33 ), 23154 – 23167 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Kanno T , KannoY , SiegelRM , JangMK , LenardoMJ , OzatoK . Selective recognition of acetylated histones by bromodomain proteins visualized in living cells . Mol. Cell13 ( 1 ), 33 – 43 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Wang R , LiQ , HelferCM , JiaoJ , YouJ . The bromodomain protein Brd4 associated with acetylated chromatin is important for maintenance of higher-order chromatin structure . J. Biol. Chem.287 ( 14 ), 10738 – 10752 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Garcia-Gutierrez P , MundiM , Garcia-DominguezM . Association of bromodomain BET proteins to the chromatin requires dimerization through the conserved motif B . J. Cell Sci.125 ( Pt 15 ), 3671 – 3680 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Picaud S , WellsC , FelletarIet al. RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain . Proc. Natl Acad. Sci. USA110 ( 49 ), 19754 – 19759 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Delmore JE , IssaGC , LemieuxMEet al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc . Cell146 ( 6 ), 904 – 917 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Fowler T , GhatakP , PriceDHet al. Regulation of MYC expression and differential JQ1 sensitivity in cancer cells . PLoS ONE9 ( 1 ), e87003 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Lockwood WW , ZejnullahuK , BradnerJE , VarmusH . Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins . Proc. Natl Acad. Sci. USA109 ( 47 ), 19408 – 19413 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Chapuy B , MckeownMR , LinCYet al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma . Cancer Cell24 ( 6 ), 777 – 790 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• You J , LiQ , WuC , KimJ , OttingerM , HowleyPM . Regulation of aurora B expression by the bromodomain protein Brd4 . Mol. Cell. Biol.29 ( 18 ), 5094 – 5103 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Mochizuki K , NishiyamaA , JangMKet al. The bromodomain protein Brd4 stimulates G1 gene transcription and promotes progression to S phase . J. Biol. Chem.283 ( 14 ), 9040 – 9048 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Yang Z , HeN , ZhouQ . Brd4 recruits P-TEFb to chromosomes at late mitosis to promote G1 gene expression and cell cycle progression . Mol. Cell. Biol.28 ( 3 ), 967 – 976 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Dawson MA , GudginEJ , HortonSJet al. Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia . Leukemia28 ( 2 ), 311 – 320 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Tang Y , GholaminS , SchubertSet al. Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition . Nat. Med.20 ( 7 ), 732 – 740 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Bhadury J , NilssonLM , Veppil MuralidharanSet al. BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma . Proc. Natl Acad. Sci. USA111 ( 26 ), E2721 – E2730 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Hussong M , BornoST , KerickMet al. The bromodomain protein BRD4 regulates the KEAP1/NRF2-dependent oxidative stress response . Cell Death Dis.5 , e1195 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Floyd SR , PacoldME , HuangQet al. The bromodomain protein Brd4 insulates chromatin from DNA damage signalling . Nature498 ( 7453 ), 246 – 250 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Gacias M , Gerona-NavarroG , PlotnikovANet al. Selective chemical modulation of gene transcription favors oligodendrocyte lineage progression . Chem. Biol.21 ( 7 ), 841 – 854 ( 2014 ).
   PubMedGoogle Scholar
• Zuber J , ShiJ , WangEet al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia . Nature478 ( 7370 ), 524 – 528 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Mertz JA , ConeryAR , BryantBMet al. Targeting MYC dependence in cancer by inhibiting BET bromodomains . Proc. Natl Acad. Sci. USA108 ( 40 ), 16669 – 16674 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Herrmann H , BlattK , ShiJet al. Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML . Oncotarget3 ( 12 ), 1588 – 1599 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Dawson MA , PrinjhaRK , DittmannAet al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia . Nature478 ( 7370 ), 529 – 533 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Da Costa D , AgathanggelouA , PerryTet al. BET inhibition as a single or combined therapeutic approach in primary paediatric B-precursor acute lymphoblastic leukaemia . Blood Cancer J3 , e126 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Chaidos A , CaputoV , GouvedenouKet al. Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762 . Blood123 ( 5 ), 697 – 705 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Trabucco SE , GersteinRM , EvensAMet al. Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma . Clin. Cancer Res.21 ( 1 ), 113 – 122 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Ceribelli M , KellyPN , ShafferALet al. Blockade of oncogenic IkappaB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors . Proc. Natl Acad. Sci. USA111 ( 31 ), 11365 – 11370 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Emadali A , RousseauxS , Bruder-CostaJet al. Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls rituximab response and tumour growth in aggressive lymphoid cancers . EMBO Mol. Med.5 ( 8 ), 1180 – 1195 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Moros A , RodriguezV , Saborit-VillarroyaIet al. Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma . Leukemia28 ( 10 ), 2049 – 2059 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• French CA . Pathogenesis of NUT midline carcinoma . Annu. Rev. Pathol.7 , 247 – 265 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Grayson AR , WalshEM , CameronMJet al. MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma . Oncogene33 ( 13 ), 1736 – 1742 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Reynoird N , SchwartzBE , DelvecchioMet al. Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyperacetylated chromatin domains . EMBO J.29 ( 17 ), 2943 – 2952 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Shimamura T , ChenZ , SoucherayMet al. Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer . Clin. Cancer Res.19 ( 22 ), 6183 – 6192 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Wyce A , DegenhardtY , BaiYet al. Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer . Oncotarget4 ( 12 ), 2419 – 2429 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Draker R , NgMK , SarcinellaE , IgnatchenkoV , KislingerT , CheungP . A combination of H2A.Z and H4 acetylation recruits Brd2 to chromatin during transcriptional activation . PLoS Genet.8 ( 11 ), e1003047 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Sahai V , KumarK , KnabLMet al. BET bromodomain inhibitors block growth of pancreatic cancer cells in three-dimensional collagen . Mol. Cancer Ther.13 ( 7 ), 1907 – 1917 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Segura MF , Fontanals-CireraB , Gaziel-SovranAet al. BRD4 sustains proliferation and represents a new target for epigenetic therapy in melanoma . Cancer Res.73 ( 20 ), 6264 – 6276 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Gallagher SJ , MijatovB , GunatilakeDet al. The epigenetic regulator I-BET151 induces BIM-dependent apoptosis and cell cycle arrest of human melanoma cells . J. Invest. Dermatol.34 ( 11 ), 2795 – 2805 ( 2014 ).
   Google Scholar
• Gallagher SJ , MijatovB , GunatilakeDet al. Control of NF-kB activity in human melanoma by bromodomain and extra-terminal protein inhibitor I-BET151 . Pigment Cell Melanoma Res.27 ( 6 ), 1126 – 1137 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Cheng Z , GongY , MaYet al. Inhibition of BET bromodomain targets genetically diverse glioblastoma . Clin. Cancer Res.19 ( 7 ), 1748 – 1759 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Pastori C , DanielM , PenasCet al. BET bromodomain proteins are required for glioblastoma cell proliferation . Epigenetics9 ( 4 ), 611 – 20 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Puissant A , FrummSM , AlexeGet al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition . Cancer Discov.3 ( 3 ), 308 – 323 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Wyce A , GanjiG , SmithemanKNet al. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models . PLoS ONE8 ( 8 ), e72967 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Henssen A , ThorT , OderskyAet al. BET bromodomain protein inhibition is a therapeutic option for medulloblastoma . Oncotarget4 ( 11 ), 2080 – 2095 ( 2013 ).
   PubMedGoogle Scholar
• Bandopadhayay P , BergtholdG , NguyenBet al. BET bromodomain inhibition of MYC-amplified medulloblastoma . Clin. Cancer Res.20 ( 4 ), 912 – 925 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Smith SG , SanchezR , ZhouMM . Privileged diazepine compounds and their emergence as bromodomain inhibitors . Chem. Biol.21 ( 5 ), 573 – 583 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Sanchez R , MeslamaniJ , ZhouMM . The bromodomain: from epigenome reader to druggable target . Biochim. Biophys. Acta1839 ( 8 ), 676 – 685 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Zhang G , PlotnikovAN , RusinovaEet al. Structure-guided design of potent diazobenzene inhibitors for the BET bromodomains . J. Med. Chem.56 ( 22 ), 9251 – 9264 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Mclure KG , GesnerEM , TsujikawaLet al. RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist . PLoS ONE8 ( 12 ), e83190 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Chung CW , WitheringtonJ . Progress in the discovery of small-molecule inhibitors of bromodomain-histone interactions . J. Biomol. Screen.16 ( 10 ), 1170 – 1185 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Seal J , LamotteY , DoncheFet al. Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A) . Bioorg. Med. Chem. Lett.22 ( 8 ), 2968 – 2972 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Chung CW , CosteH , WhiteJHet al. Discovery and characterization of small molecule inhibitors of the BET family bromodomains . J. Med. Chem.54 ( 11 ), 3827 – 3838 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Mirguet O , LamotteY , DoncheFet al. From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151 . Bioorg. Med. Chem. Lett.22 ( 8 ), 2963 – 2967 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Gehling VS , HewittMC , VaswaniRGet al. Discovery, design, and optimization of isoxazole azepine BET inhibitors . ACS Med. Chem. Lett.4 ( 9 ), 835 – 840 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Fish PV , FilippakopoulosP , BishGet al. Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit . J. Med. Chem.55 ( 22 ), 9831 – 9837 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Vidler LR , FilippakopoulosP , FedorovOet al. Discovery of novel small-molecule inhibitors of BRD4 using structure-based virtual screening . J. Med. Chem.56 ( 20 ), 8073 – 8088 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Muvva C , SingamER , RamanSS , SubramanianV . Structure-based virtual screening of novel, high-affinity BRD4 inhibitors . Mol. Biosyst.10 ( 9 ), 2384 – 2397 ( 2014 ).
   PubMedGoogle Scholar
• Lucas X , WohlwendD , HugleMet al. 4-Acyl pyrroles: mimicking acetylated lysines in histone code reading . Angew. Chem. Int. Ed. Engl.52 ( 52 ), 14055 – 14059 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Lefker BA , ShinJ , WilliamsCet al. Design and chemoproteomic functional characterization of a chemical probe targeted to bromodomains of BET family proteins . MedChemComm.51871 – 1879 ( 2014 ).
   Web of Science ®Google Scholar
• Philpott M , YangJ , TumberTet al. Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery . Mol. Biosyst.7 ( 10 ), 2899 – 2908 ( 2011 ).
   PubMedGoogle Scholar
• Picaud S , Da CostaD , ThanasopoulouAet al. PFI-1 - A highly selective protein interaction inhibitor targeting BET bromodomains . Cancer Res.73 ( 11 ), 3336 – 3346 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Ciceri P , MullerS , O’mahonyAet al. Dual kinase-bromodomain inhibitors for rationally designed polypharmacology . Nat. Chem. Biol.10 ( 4 ), 305 – 312 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Schulze J , MoosmayerD , WeiskeJet al. Cell-based protein stabilization assays for the detection of interactions between small-molecule inhibitors and BRD4 . J. Biomol. Screen.20 ( 2 ), 180 – 189 ( 2014 ).
   PubMedGoogle Scholar
• Zhang G , LiuR , ZhongYet al. Down-regulation of NF-kappaB transcriptional activity in HIV-associated kidney disease by BRD4 inhibition . J. Biol. Chem.287 ( 34 ), 28840 – 28851 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Liu R , ZhongY , LiXet al. Role of transcription factor acetylation in diabetic kidney disease . Diabetes63 ( 7 ), 2440 – 2453 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Mirguet O , GosminiR , ToumJet al. Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains . J. Med. Chem.56 ( 19 ), 7501 – 7515 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Garnier JM , SharpPP , BurnsCJ . BET bromodomain inhibitors: a patent review . Expert Opin. Ther. Pat.24 ( 2 ), 185 – 199 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Schmees N , HaendlerB , LejeunePet al. New benzazepine BET-inhibitors with improved oral bioavailability . Presented at : 105th Annual Meeting of the American Association for Cancer Research ; San Diego, CA, USA5–9 April 2014 .
   Google Scholar
• Filippakopoulos P , PicaudS , FedorovOet al. Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family . Bioorg. Med. Chem.20 ( 6 ), 1878 – 1886 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Hewings DS , WangM , PhilpottMet al. 3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands . J. Med. Chem.54 ( 19 ), 6761 – 6770 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Bamborough P , BrownMJ , ChristopherJA , ChungCW , MellorGW . Selectivity of kinase inhibitor fragments . J. Med. Chem.54 ( 14 ), 5131 – 5143 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Hay D , FedorovO , FilippakopoulosPet al. The design and synthesis of 5- and 6-isoxazolylbenzimidazoles as selective inhibitors of the BET bromodomains . MedChemComm4 ( 1 ), 140 – 144 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Shahbazi J , ScarlettCJ , NorrisMDet al. Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1 . Oncotarget5 ( 12 ), 4257 – 4268 ( 2014 ).
   PubMedGoogle Scholar
• Gosmini R , NguyenVL , ToumJet al. The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up-regulator and selective BET bromodomain inhibitor . J. Med. Chem.57 ( 19 ), 8111 – 8131 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Arnold LD , ForemanKW , WernerDS : WO2013033268 A2(PCT/US2012/052941) ( 2013 ).
   Google Scholar
• Mirguet O , LamotteY , ChungCWet al. Naphthyridines as novel BET family bromodomain inhibitors . ChemMedChem9 ( 3 ), 580 – 589 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Chung CW , DeanAW , WoolvenJM , BamboroughP . Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery . J. Med. Chem.55 ( 2 ), 576 – 586 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Zhao L , CaoD , ChenTet al. Fragment-based drug discovery of 2-thiazolidinones as inhibitors of the histone reader BRD4 bromodomain . J. Med. Chem.56 ( 10 ), 3833 – 3851 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Ito T , UmeharaT , SasakiKet al. Real-time imaging of histone H4K12-specific acetylation determines the modes of action of histone deacetylase and bromodomain inhibitors . Chem. Biol.18 ( 4 ), 495 – 507 ( 2011 ).
   PubMedGoogle Scholar
• Fedorov O , LingardH , WellsCet al. [1,2,4]triazolo[4,3-a]phthalazines: inhibitors of diverse bromodomains . J. Med. Chem.57 ( 2 ), 462 – 476 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Dittmann A , WernerT , ChungCWet al. The commonly used PI3-kinase probe LY294002 is an inhibitor of BET bromodomains . ACS Chem. Biol.9 ( 2 ), 495 – 502 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Martin MP , OlesenSH , GeorgGI , SchonbrunnE . Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains . ACS Chem. Biol.8 ( 11 ), 2360 – 2365 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Ember SW , ZhuJY , OlesenSHet al. Acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors . ACS Chem. Biol.9 ( 5 ), 1160 – 1171 ( 2014 ).
   PubMed Web of Science ®Google Scholar